Barc Lab and OWL Metabolomics Announce Strategic Partnership on Deploying Metabolomic Technology in Clinical Trials

Barc Lab and OWL Metabolomics announced that they have entered into a global strategic partnership combining Barc Lab’s industry leading central lab services with OWL Metabolomics’ world class metabolomics technology.

This strategic partnership between Barc Lab and OWL Metabolomics will provide a broad range of clinical support solutions for the expanding number of biopharmaceutical companies active in non-alcoholic steatohepatitis (NASH) research leveraging cutting-edge, metabolomic technology and expertise. Combining the unique strengths of a major international central laboratory (Barc Lab) with a metabolomics specialty laboratory (OWL) focusing on NASH and liver diseases will create valuable synergies for involved customers worldwide.

This partnership will support our clients through their quest to find the right therapies for their patients and gain additional insight into the true biological impact of their compounds. Despite the growing prevalence of NASH, there are currently no approved treatments for the disease beyond liver transplant.

The constellation of risk factors for NASH has generated a multitude of targets and there is an obvious need to bring promising treatments through clinical trials and to patients quickly. OWL Metabolomics’ technology allows for the identification of over 1000 small metabolites in a single sample, hence providing a comprehensive picture of the metabolome. This type of next-generation precision metabolomics can yield a thorough assessment of NASH complexity by helping the analysis of metabolic alterations which play a main role in the progression of NASH.

Mario PAPILLON, Barc Lab’s CEO declared: “This partnership is truly a powerful combination and is a natural progression from Barc Lab’s leadership position in NASH research. It is my pleasure to announce that OWL technology platform can now be accessed from Barc Lab. OWL is known for their strength in the metabolomics field, particularly in liver disease, and offers valuable insight into biological systems. This collaboration will allow us to provide our customers with the solutions they need to develop tailored treatments for NASH patients and address this desperate unmet medical need.”

“We are proud of having formed this exciting new alliance with Barc Lab as a major company milestone for OWL Metabolomics. We are confident that the two companies together will bring a very positive impact to the important field of NASH research and become valued reference service providers for clinical trials in liver disease research,” said Pablo ORTIZ, CEO of OWL Metabolomics.

Leave A Reply

Your email address will not be published.